Results 11 to 20 of about 4,861,637 (146)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma [PDF]

Biomedicines, 2023
The clinical management of metastatic melanoma has been changed by BRAF (BRAFi) and MEK inhibitors (MEKi), which represent a standard treatment for BRAF-mutant melanoma.
Ernesto Rossi, Giovanni Schinzari, Francesco Cellini, Mario Balducci, Mariangela Pasqualoni, Brigida Anna Maiorano, Bruno Fionda, Silvia Longo, Francesco Deodato, Alessandro Di Stefani, Ketty Peris, Maria Antonietta Gambacorta, Giampaolo Tortora   +12 more
doaj   +3 more sources

The Effectiveness and Safety of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Oligoprogressive Breast Cancer: A Systematic Review

Current Oncology, 2023
Stereotactic body radiotherapy (SBRT) has emerged as a technique to treat oligoprogressive sites among patients with breast cancer who are otherwise doing well on systemic therapy. This study systematically reviewed the efficacy and safety of SBRT in the
Bernie Yan, Sherif Ramadan, Katarzyna J. Jerzak, Alexander V. Louie, Elysia Donovan   +4 more
doaj   +2 more sources

Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR) [PDF]

BMC Cancer, 2021
Background The enhanced knowledge of cancer biology has led to considerable advancement in systemic therapy for advanced breast cancer. Recently, studies showed that cyclin-dependent kinase (CDK) 4/6 inhibitor, when added to endocrine therapy, had ...
Reem Alomran, Michelle White, Melissa Bruce, Mathias Bressel, Susan Roache, Lama Karroum, Gerard G. Hanna, Shankar Siva, Shom Goel, Steven David   +9 more
doaj   +2 more sources

Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer

Clinical and Translational Radiation Oncology, 2023
Introduction: The role of local ablative treatments, including stereotactic body radiotherapy (SBRT), is an area of active research in oligometastatic patients. Small cell lung cancer (SCLC) has a poor prognosis, with common diffuse metastatic evolution.
Antonin Levy, Jonathan Khalifa, Etienne Martin, Angela Botticella, Clément Quevrin, Pernelle Lavaud, Mihaela Aldea, Benjamin Besse, David Planchard, Fabrice Barlesi, Eric Deutsch, Carole Massabeau, Jérôme Doyen, Cécile Le Péchoux   +13 more
doaj   +2 more sources

Progression-directed therapy in patients with oligoprogressive castration-resistant prostate cancer [PDF]

Investigative and Clinical Urology
Purpose: Oligoprogressive lesions are observed in a subset of patients who progress to castration-resistant prostate cancer (CRPC), while other lesions remain controlled by systemic therapy. This study evaluates the impact of progression-directed therapy
Jun Nyung Lee, Mi Young Kim, Jae Hoon Kang , Jun-Koo Kang, Jae-Wook Chung, Yun-Sok Ha, Seock Hwan Choi, Bum Soo Kim, Hyun Tae Kim, Tae-Hwan Kim, Eun Sang Yoo, See Hyung Kim, Tae Gyun Kwon   +12 more
doaj   +2 more sources

Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease. [PDF]

Rep Pract Oncol Radiother, 2021
BACKGROUND: Stereotactic body radiation therapy (SBRT) as a form of noninvasive treatment that is becoming increasingly used to manage cancers with adrenal gland metastases. There is a paucity of data on safety and efficacy of this modality.
Reshko LB, Gaskins JT, Silverman CL, Dunlap NE.   +3 more
europepmc   +3 more sources

Role of Consolidative Stereotactic Body Radiation Therapy in Oligoresistant/Oligoprogressive Pulmonary Parenchymal Metastases [PDF]

Cancer Management and Research, 2022
Tanju Berber,1 Abdullah Sakin2 1Department of Radiation Oncology, Okmeydani Training and Research Hospital, Istanbul, Turkey; 2Department of Medical Oncology, Medipol University, Bahçelievler Medipol Hospital, Istanbul, TurkeyCorrespondence: Tanju Berber,
Berber T, Sakin A
doaj   +2 more sources

Salvage Ultrasound-Guided Robot-Assisted Video-Endoscopic Inguinal Lymphadenectomy (RAVEIL) as a Metastasis-Directed Therapy (MDT) in Oligoprogressive Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case Report and Review of the Literature

Current Oncology
Background: Metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to progression despite androgen deprivation therapy (ADT).
Rafał B. Drobot, Marcin Lipa, Artur A. Antoniewicz   +2 more
doaj   +2 more sources

Oligoprogressive renal cell carcinoma: What is the role of surgery? [PDF]

BJU Int
Objective To provide an overview of the biological mechanism and pattern of oligoprogression in renal cell carcinoma (RCC) and the most updated role of surgery in this setting, highlighting scientific gaps and informing future implications. Methods A non‐systematic search of PubMed/MEDLINE was performed in August 2025 including guidelines, reviews, and
Re C, Ince WHJ, Bickley L, Blackmur JP, Ismail MH, Kyeremeh J, Kuusk T, Serrao EM, Jones JO, Stewart GD.   +9 more
europepmc   +2 more sources

Radiotherapy for oligoprogressive disease in non-small cell lung cancer treated with pembrolizumab in first-line setting: a retrospective study. [PDF]

Transl Lung Cancer Res
Santonja C, Gougis P, Dumas E, Rolland Debord C, Merle P, Belliere A, Campedel L, Abbar B.   +7 more
europepmc   +2 more sources